Mibefradil alters intracellular calcium concentration by activation of phospholipase C and IP(3) receptor function

Mibefradil is a tetralol derivative originally developed as an antagonist of T-type voltage-gated calcium (Ca(2+)) channels to treat hypertension when used at nanomolar dosage. More recently, its therapeutic application in hypertension has declined and has been instead repurposed as a treatment of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza Bomfim, Guilherme H., Mitaishvili, Erna, Aguiar, Talita Ferreira, Lacruz, Rodrigo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607413/
https://www.ncbi.nlm.nih.gov/pubmed/35006468
http://dx.doi.org/10.1186/s43556-021-00037-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607413/
https://www.ncbi.nlm.nih.gov/pubmed/35006468
http://dx.doi.org/10.1186/s43556-021-00037-0

Ejemplares similares